湖南汉森制药股份有限公司 2025 年半年度报告全文 2025 年半年度报告 证券简称：汉森制药 证券代码：002412 2025 年 8 月 1 湖南汉森制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人刘正清、主管会计工作负责人戴江洪及会计机构负责人(会计 主管人员)郭志蓉声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司在本报告第三节"管理层讨论与分析"中"十、公司面临的风险和 应对措施"部分，详细描述了公司经营中可能面临的风险及应对措施，敬请 投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | 湖南汉森制药股份有限公司 2025 年半年度报告全文 备查文件目录 一、载有法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报告 文本； 二、报告期内在中国证监会指定信息披露媒体披露过的公告正本及原稿； 三、载有 ...

一、董事会会议召开情况 湖南汉森制药股份有限公司（以下简称"公司"）第六届董事会第八次会议 于 2025 年 8 月 22 日在公司二楼会议室以通讯方式召开，本次会议由公司董事 长刘正清先生召集并主持，会议通知于 2025 年 8 月 11 日以专人递送、传真及 电子邮件等方式送达给全体董事、监事和高级管理人员。本次会议应参加会议董 事 7 人，实际参加会议董事 7 人，公司监事、高级管理人员列席了本次会议。 本次会议的召集、召开符合《中华人民共和国公司法》及《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过了《2025 年半年度报告及摘要》 《2025 年半年度报告》全文详见 2025 年 8 月 26 日公司指定信息披露网站 巨潮资讯网（www.cninfo.com.cn）；《2025 年半年度报告摘要》（公告编号：2025-016） 同日刊载于《证券时报》《中国证券报》《上海证券报》《证券日报》和巨潮资 讯网（www.cninfo.com.cn）。 本议案已经公司董事会审计委员会审议通过。 证券代码：002412 证券简称：汉森制药 公告编号：2025-015 湖南汉森制药股份有限公司 第六届 ...

Group 1 - The company Hansen Pharmaceutical stated that as of July 31, 2025, the total number of shareholders on the consolidated shareholder register, including credit accounts, is 24,418 [2]

再者，医疗保健板块与中药板块紧密相关。中药在医疗保健领域的应用广泛，如中药饮片、中成药、中 药保健品等。中药板块的发展将带动医疗保健产品的创新和升级，促进医疗保健机构开展更多与中药相 关的服务项目，如中医理疗、中药养生等，满足消费者日益增长的健康需求。 不过，中药行业在发展过程中也面临一些挑战，如中药质量标准的统一、中药材资源的可持续利用等。 但在政策支持、市场需求增长和行业自身发展的大背景下，中药板块及相关受益领域未来仍具有较大的 发展潜力。投资者在关注该板块投资机会时，需综合考虑各种因素，谨慎做出投资决策。 来源：金融界 首先是中药材种植板块。中药产业的发展离不开优质的中药材原料，对中药材的需求增加将直接带动中 药材种植规模的扩大。这将促进中药材种植户提高种植技术，增加收入，同时也为中药材种植相关的农 业服务企业带来更多的业务机会，如种子种苗供应、农药化肥销售、农业技术咨询等。 其次，中药研发板块也将受益。政策鼓励中药创新，支持企业加大研发投入，开展中药新药、经典名方 等研发项目。这将推动中药研发机构和企业加强技术创新，提高研发水平，加速中药创新成果的转化， 为中药行业的可持续发展提供动力。 今日股市交易 ...

Group 1 - The company is currently in the process of scaling up the production of its new traditional Chinese medicine product, Cangrong Granules, which is in the pilot testing phase [1] - The Tianma Xingnao Capsule is designed to nourish the liver and kidneys, alleviate pain, and is used for symptoms related to liver and kidney deficiency, such as headaches, dizziness, memory decline, insomnia, sluggishness, tinnitus, and lower back pain [1] - For detailed information, the company refers investors to its 2024 annual report [1]

证券日报网讯汉森制药8月14日在互动平台回答投资者提问时表示，公司制定了《未来三年（2024— 2026年）股东回报规划》，明确以现金分红为主的基本原则，强化回报股东意识。公司将继续聚焦主 业，通过提升盈利能力维护投资者信心。 （文章来源：证券日报） ...

Group 1 - The stock price of Hansen Pharmaceutical is reported at 6.84 yuan as of August 13, 2025, reflecting a decrease of 0.44% compared to the previous trading day [1] - The trading volume on the same day was 105,621 hands, with a transaction amount of 0.72 billion yuan [1] - Hansen Pharmaceutical's main business includes the research, production, and sales of traditional Chinese medicine, covering areas such as digestive system medications and cardiovascular drugs [1] Group 2 - As of July 31, 2025, the total number of shareholders for Hansen Pharmaceutical is reported to be 24,418 [1] - The company is associated with concepts such as traditional Chinese medicine and the Hunan region [1]

证券日报网讯汉森制药8月5日在互动平台回答投资者提问时表示，截至2025年7月31日，公司含信用账 户合并股东名册的股东总数为24，418户。 （文章来源：证券日报） ...

Group 1 - The company acknowledges the impact of national "anti-involution" and "medical procurement" policies on the industry, suggesting a positive influence on its operations and product effectiveness [1] - The company emphasizes its commitment to closely monitor industry trends and enhance its core competitiveness in response to these policies [1]

Group 1 - The core viewpoint of the articles highlights the significant progress made by Yiyang City in brand building, with three local brands recognized in national evaluations, indicating a strong competitive advantage in regional branding, traditional industries, and the pharmaceutical health sector [1][2] - The three brands that made the list are Anhua Black Tea, Hunan Shali Socks, and Hunan Hansen Pharmaceutical, showcasing Yiyang's differentiated competitive strengths in their respective fields [1] - Anhua Black Tea ranked 7th in the regional brand category, becoming one of the 36 regional brands with a value exceeding 10 billion yuan, and is positioned as a key player in rural revitalization [1][2] Group 2 - Yiyang's government has implemented a brand-strengthening strategy as a key driver for high-quality economic development, establishing a collaborative mechanism involving government guidance, departmental coordination, enterprise participation, and social involvement [2] - The market regulatory department in Yiyang has focused on enhancing brand value for enterprises by simplifying brand registration processes and providing one-on-one guidance, significantly improving efficiency in brand building [2] - Yiyang has actively promoted quality improvement initiatives, encouraging enterprises to pursue various certifications and providing comprehensive quality management support, which has strengthened brand awareness and contributed to the city's economic development [2]